Relevant Articles About HER2+ Breast Cancer Research and Clinical Trials
The posts you requested could not be found. Try changing your module settings or create some new posts.
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Privacy Policy
KEY TAKEAWAYS The study aimed to define the prevalence of MMR-D and assess the predictive value of MMR protein expression in patients with cervical cancer. The low MSH-2 expression is an independent predictor of poor survival. The early detection of cervical cancer...
KEY TAKEAWAYS The study aimed to conduct a bibliometric analysis to summarize the trends in research on resistance to EGFR TKIs in patients with EGFR-mutant NSCLC. The study identified hot spots in EGFR-TKI resistance in NSCLC therapeutics. Activating mutations in...
KEY TAKEAWAYS The study aimed to Phenotype PN symptoms and identify a correlation with ctDNA variables. The study revealed an association between genomic alterations and heightened genomic instability, which can guide tailored treatment protocols. Breast cancer...
Background Immune checkpoint blockade targeting the adaptive immune system has revolutionized the treatment of cancer. Despite impressive clinical benefits observed, patient subgroups remain non-responsive underscoring the necessity for combinational therapies harnessing additional immune cells. Natural killer …
Background Tertiary lymphoid structures (TLSs) are thought to stimulate antitumor immunity and positively impact prognosis and response to immune checkpoint blockade. In gastric cancers (GCs), however, TLSs are predominantly found in GC with poor prognosis and …
Background Patients with mismatch repair-deficient (MMRd) endometrial cancer (EC) can derive great benefit from immune checkpoint inhibitors (ICI). However not all responses and predictors of primary resistance are lacking. Methods We compared the immune tumor microenvironment of MMRd …
Background Fludarabine in combination with cyclophosphamide (FC) is the standard lymphodepletion regimen for CAR T-cell therapy (CAR T). A national fludarabine shortage in 2022 necessitated the exploration of alternative regimens with many centers employing single-agent bendamustine …